ClinicalTrials.gg
TerminatedNCT00251589Updated Mar 6, 2015Results posted

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

A Phase 1/2 interventional study of Vorinostat and Vorinostat in Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This trial is being closed based on lack of substantive efficacy, slow accrual and overall tolerance in patients treated to date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 19
23 · median 21
Started
2006
with 1 other
Phase 1/2
4 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
6 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 4 in phase 1/2, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The reason for this study will be to find the safest maximum tolerated dose of oral vorinostat in combination with erlotinib [Tarceva (TM)] that can be given to patients with lung cancer who have relapsed or failed other therapy for the disease. Once the safest maximum tolerated dose of vorinostat is determined, patients enrolled in the clinical trial will continue vorinostat and erlotinib for up to 8 months. Safety and effectiveness will also be evaluated.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Relapsed Non-Small-Cell Lung Cancer
  • Refractory Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18 years of age and older with a confirmed diagnosis of non-small-cell lung cancer (NSCLC) who have failed at least one prior treatment for NSCLC.
  • Patients must have proven disease by CT scan or MRI.
  • Patients must be at least 4 weeks from any chemotherapy for cancer or from any surgeries or from any treatment using an drug.
  • Patients must be 2 weeks out from radiation therapy.
  • At screening the patient must have normal lab results and can not be pregnant.
  • Women and men must agree to practice adequate during the study.
  • Patient has the ability to understand and sign the consent form.

Exclusion criteria

Exclusion Criteria:

  • Patient had prior treatment with vorinostat or erlotinib.
  • Patient has any of the following conditions: active infections including or C, unstable , swallowing difficulties, heart problems, significant eye abnormalities, drug or alcohol abuse, mental illness or pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk

    Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion

    Drug: Vorinostat · Drug: erlotinib

  • Experimental
    Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk

    Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.

    Drug: Vorinostat · Drug: erlotinib

  • Experimental
    Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk

    Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.

    Drug: Vorinostat · Drug: erlotinib

  • Experimental
    Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk

    Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.

    Drug: Vorinostat · Drug: erlotinib

Interventions

  • Vorinostat 200 mg twice a day for 3 days a week.

    Also known as: MK0683, Zolinza®

  • Vorinostat 300 mg once a day for 3 days a week.

    Also known as: MK0683, Zolinza®

  • Vorinostat 300 mg twice a day for 3 days a week.

    Also known as: MK0683, Zolinza®

  • Vorinostat 400 mg once a day for 21 out of 28 days.

    Also known as: MK0683, Zolinza®

  • erlotinib 150 mg once a day.

    Also known as: Tarceva ®

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study

    Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase I portion of the study.

    Time frame: Day 1 to 28 in the Phase I portion of the study

  2. Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study

    Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase II portion of the study.

    Time frame: Day 1 to 28 in the Phase II portion of the study

Secondary outcomes

  1. Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)

    An unconfirmed partial response is defined as a partial response that has not been confirmed by a follow up CT scan (or MRI) at least 4 weeks after the criteria for response are first met. (A partial response is defined as an at least 30% reduction in the sum of the longest diameter of the target lesions. Non-target lesions must be at least stable)

    Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate

  2. Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)

    Stable disease is defined as less than a radiographic partial response, but not progressive disease

    Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate

  3. Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)

    Progressive disease is defined as a ≥20% increase in the sum of the longest diameter, the appearance of one or more new lesions and/or unequivocal progression of non-target lesions by conventional or spiral CT or MRI

    Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate

  4. Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)

    First documentation of Progressive Disease (PD) occurring \> 8 weeks on study.

    Time frame: Every 57 days beginning with Cycle 3 (Week 8), or more frequently if appropriate

  5. Progression-free Survival

    Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded).

    Time frame: Day 1 to disease progression or death

07

Results

Posted Mar 10, 2009
Limitations and caveats
Due to the slow pace of patient accrual, failure to observe meaningful efficacy in treated patients, and overall intolerance of the combination regimen, the study was terminated prematurely on 12-Oct-2007.

Participant flow

This study was conducted at 12 investigative sites in the United States. The first patient's first visit was 30 March 2006. The study was terminated early on 12 Oct 2007 and the last patient's last visit was 30 Oct 2007.

Participant flow — Overall Study
MilestoneVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Started16322
Completed1000
Not completed15322
Withdrew: Adverse event5121
Withdrew: Withdrawal by subject1100
Withdrew: Discontinued due to progressive disease9101

Outcome measures

PrimaryDose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study

Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase I portion of the study.

Time frame:
Day 1 to 28 in the Phase I portion of the study
Reported as:
Number · Participants
Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study0221
SecondaryUnconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)

An unconfirmed partial response is defined as a partial response that has not been confirmed by a follow up CT scan (or MRI) at least 4 weeks after the criteria for response are first met. (A partial response is defined as an at least 30% reduction in the sum of the longest diameter of the target lesions. Non-target lesions must be at least stable)

Time frame:
Every 57 days beginning with Cycle 3, or more frequently if appropriate
Reported as:
Number · Participants
Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)0000
PrimaryDose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study

Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase II portion of the study.

Time frame:
Day 1 to 28 in the Phase II portion of the study
Reported as:
Number · Participants
Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study3———
Post-hocDose Limiting Toxicity Occurring in Cycles 2 and Beyond of the Phase II Portion of the Study

Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycles 2 and beyond of the Phase II portion of the study.

Time frame:
After day 28 in the Phase II portion of the study
Reported as:
Number · Participants
Dose Limiting Toxicity Occurring in Cycles 2 and Beyond of the Phase II Portion of the Study
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Dose Limiting Toxicity Occurring in Cycles 2 and Beyond of the Phase II Portion of the Study3———
SecondaryStable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)

Stable disease is defined as less than a radiographic partial response, but not progressive disease

Time frame:
Every 57 days beginning with Cycle 3, or more frequently if appropriate
Reported as:
Number · Participants
Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)6111
SecondaryProgressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)

Progressive disease is defined as a ≥20% increase in the sum of the longest diameter, the appearance of one or more new lesions and/or unequivocal progression of non-target lesions by conventional or spiral CT or MRI

Time frame:
Every 57 days beginning with Cycle 3, or more frequently if appropriate
Reported as:
Number · Participants
Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)7000
SecondaryDisease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)

First documentation of Progressive Disease (PD) occurring \> 8 weeks on study.

Time frame:
Every 57 days beginning with Cycle 3 (Week 8), or more frequently if appropriate
Reported as:
Number · Participants
Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)
ParticipantsVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)3000
SecondaryProgression-free Survival

Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded).

Time frame:
Day 1 to disease progression or death
Reported as:
Mean · Days
Progression-free Survival
DaysVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk
Progression-free Survival57 (26 to 113)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk—6/16 (37.5%)16/16 (100%)
Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk—2/3 (66.7%)3/3 (100%)
Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk—2/2 (100%)2/2 (100%)
Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk—1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
DiarrhoeaGastrointestinal disorders1/160/31/20/2
Cerebral ischaemiaNervous system disorders0/160/30/21/2
Deep vein thrombosisVascular disorders0/160/31/20/2
Confusional statePsychiatric disorders0/161/30/20/2
Exfoliative rashSkin and subcutaneous tissue disorders0/161/30/20/2
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/160/30/20/2
NauseaGastrointestinal disorders1/160/30/20/2
VomitingGastrointestinal disorders1/160/30/20/2
InfectionInfections and infestations1/160/30/20/2
Pneumococcal bacteraemiaInfections and infestations1/160/30/20/2
Most frequent other events
Showing 10 of 107
Most frequent other events
EventVorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk
ConstipationGastrointestinal disorders1/161/30/22/2
DiarrhoeaGastrointestinal disorders13/163/32/22/2
NauseaGastrointestinal disorders13/162/32/22/2
VomitingGastrointestinal disorders6/161/32/22/2
FatigueGeneral disorders8/161/30/22/2
Weight decreasedInvestigations6/161/32/21/2
RashSkin and subcutaneous tissue disorders9/163/30/22/2
AnorexiaMetabolism and nutrition disorders10/161/31/20/2
PhotopsiaEye disorders0/160/30/21/2
Breath odourGastrointestinal disorders0/160/30/21/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wkTotal
Mean53.0 ± 4.3666.0 ± 8.4948.5 ± 20.5159.1 ± 11.5960.7 ± 11.41
Age, Customized
Age, Customized(Participants)Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wkTotal
≤ 65 years1131217
> 65 years50106
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wkVorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wkTotal
Female821112
Male811111
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2005
First posted
Nov 10, 2005
Start
Jan 2006
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Mar 10, 2009
Last update
Mar 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00251589
Responsible party
Sponsor
First posted
Nov 10, 2005
Start date
Jan 2006
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Mar 10, 2009
Last update
Mar 6, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion